Vision & Strategy
We believe that the next frontier in immunotherapy will harness the power of Natural Killer Cells to defeat cancer and severe acute infectious diseases.
Cytovia Therapeutics takes a holistic bench-to-bedside approach, applying both first and best-in-class technologies to address the toughest medical challenges.
We are developing CARNK cell therapy by combining production of NK cells from induced pluripotent stem cells (iPSC) with next generation gene-editing.
We are developing multi-functional NK engager drug candidates by leveraging its proprietary multi-specific antibody platform.